In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies
Friday, 24 June, 2005
The sale of Pharmanet Group's (ASX:PNO) wholly owned subsidiary Medical Products Group, to Advance Healthcare (ASX:AHG), has been completed. A 90-day convertible note has been issued by Advance to Pharmanet, satisfying the $400,000 settlement payment.
David Kenley, VP corporate development and one of the founders of Metabolic Pharmaceuticals (ASX:MBP), has resigned from the company to become CEO of Xceed Biotechnology (ASX:XBL). Kenley will leave Metabolic on 1 July and join Xceed in mid July.
Henry Bosch has been appointed as a non-executive director of Genetic Technologies (ASX:GTG).
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
